Key Takeaways
- • Forward P/E valuation of 14.79x places CVC Capital Partners at a discount to European capital markets industry average of 13.6x, with trailing P/E of 16.61x, suggesting relative value positioning as of mid-2026.
- • Market capitalization of €13.14–€13.67 billion with enterprise value of €14.20 billion reflects the firm's scale in the alternative asset management space, though trading well below 52-week highs of €18.00.
- • Current stock price of €12.64–€12.97 (as of late June 2026) represents significant pullback from earlier 2026 levels, with analyst consensus 12-month price target of €17.04 (range: €13.40–€21.00), implying 32–66% upside depending on path to target.
- • Performance-related earnings guidance of €600–700 million for 2026–2027 substantially trails analyst expectations of €1.0 billion, signaling potential headwinds in fee generation and deal performance that may pressure near-term earnings growth.
- • Dividend yield of 3.74% provides income support, while valuation multiples (P/S of 7.56x, P/B ratio in current reporting, PEG of 1.15) suggest the firm trades in line with normalized growth expectations for the alternative asset management sector.
Summary
CVC Capital Partners plc (Z1W.F, XAMS:CVC) trades at a forward price-to-earnings ratio of 14.79x as of late June 2026, with a trailing P/E of 16.61x, positioning the firm at what valuation specialists consider fair value relative to its European capital markets peer group. The company's market capitalization stands between €13.14 billion and €13.67 billion, with an enterprise value of €14.20 billion, reflecting its established position as a major alternative asset manager.
The stock has experienced notable compression from its 52-week high of €18.00, currently trading near €12.64–€12.97. This pullback comes amid disclosed guidance that performance-related earnings for the 2026–2027 period are expected to reach only €600–700 million—a material miss relative to analyst consensus expectations of approximately €1.0 billion. This earnings shortfall signals potential challenges in the firm's deal pipeline, portfolio performance, or fee realization, which may weigh on near-term earnings trajectory and investor sentiment.
Analyst coverage remains constructive, with a consensus 12-month price target of €17.04 across ten analyst estimates, though the range is wide (€13.40–€21.00), reflecting divergent views on execution and macro headwinds. At current prices, the upside to consensus suggests 32–66% potential appreciation depending on analyst positioning. Relative valuation metrics indicate moderate attractiveness: the firm trades at a P/E ratio of 11.3–12.11x depending on calculation method, below the industry average of 13.6x, with a price-to-sales ratio of 7.56x and a PEG ratio of 1.15x, all suggesting normalized growth expectations are priced in.
The 3.74% dividend yield provides income support to the valuation, though the earnings guidance miss may create near-term pressure on capital allocation and distribution capacity if performance metrics continue to underperform. Institutional investors should monitor the firm's actual performance-related earnings realization against the €600–700 million guidance and track portfolio valuations, fundraising traction, and management commentary on deployment opportunities in the alternative asset management environment.
The stock has experienced notable compression from its 52-week high of €18.00, currently trading near €12.64–€12.97. This pullback comes amid disclosed guidance that performance-related earnings for the 2026–2027 period are expected to reach only €600–700 million—a material miss relative to analyst consensus expectations of approximately €1.0 billion. This earnings shortfall signals potential challenges in the firm's deal pipeline, portfolio performance, or fee realization, which may weigh on near-term earnings trajectory and investor sentiment.
Analyst coverage remains constructive, with a consensus 12-month price target of €17.04 across ten analyst estimates, though the range is wide (€13.40–€21.00), reflecting divergent views on execution and macro headwinds. At current prices, the upside to consensus suggests 32–66% potential appreciation depending on analyst positioning. Relative valuation metrics indicate moderate attractiveness: the firm trades at a P/E ratio of 11.3–12.11x depending on calculation method, below the industry average of 13.6x, with a price-to-sales ratio of 7.56x and a PEG ratio of 1.15x, all suggesting normalized growth expectations are priced in.
The 3.74% dividend yield provides income support to the valuation, though the earnings guidance miss may create near-term pressure on capital allocation and distribution capacity if performance metrics continue to underperform. Institutional investors should monitor the firm's actual performance-related earnings realization against the €600–700 million guidance and track portfolio valuations, fundraising traction, and management commentary on deployment opportunities in the alternative asset management environment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.